A5013146671- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- Hematopoietic Stem Cell Transplantation
- Retinoids in leukemia and cellular processes
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
- Neutropenia and Cancer Infections
- Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Childhood Cancer Survivors' Quality of Life
- Platelet Disorders and Treatments
- Blood Coagulation and Thrombosis Mechanisms
- Blood groups and transfusion
- Glycosylation and Glycoproteins Research
- Hematological disorders and diagnostics
- Bone and Joint Diseases
- Protein Degradation and Inhibitors
- Hemoglobinopathies and Related Disorders
- Heme Oxygenase-1 and Carbon Monoxide
- Polyomavirus and related diseases
- Monoclonal and Polyclonal Antibodies Research
- T-cell and Retrovirus Studies
- Immune Cell Function and Interaction
Kanazawa University
2015-2024
Kanazawa University Hospital
1993-2023
Nagoya University
2005-2022
Nagasaki University
2005-2022
NTT Medical Center
2022
National Hospital Organization Kyushu Cancer Center
2022
Sapporo Hokuyu Hospital
2022
Tosei General Hospital
2022
Saitama Medical University
2022
Tokyo Medical and Dental University
2022
A novel therapeutic approach is urgently needed for BCR-ABL-positive acute lymphoblastic leukemia (ALL). In this study, we assessed the efficacy and feasibility of chemotherapy combined with imatinib.A phase II study imatinib-combined was conducted newly diagnosed ALL in adults. Eighty patients were entered into trial between September 2002 January 2005.Remission induction therapy resulted complete remission (CR) 77 (96.2%), resistant disease one patient, early death two patients, as well...
PURPOSE We conducted a multicenter study of differentiation therapy with all-trans retinoic acid (ATRA) followed by intensive chemotherapy in patients newly diagnosed acute promyelocytic leukemia (APL) and analyzed the prognostic factors for predicting complete remission (CR), event-free survival (EFS), disease-free (DFS). PATIENTS AND METHODS All received ATRA until CR. If had an initial leukocyte count greater than 3.0 x 10(9)/L, they daunorubicin (DNR) behenoyl cytarabine (BHAC). During...
It was recently recognized that some chronic myeloid leukemia patients with a complete molecular response could sustain after discontinuation of imatinib. To characterize the clinical outcomes and profiles phase who discontinue imatinib, we conducted nationwide survey in Japan. Among 3,242 imatinib-treated patients, identified 50 had discontinued imatinib for at least six months; these analyzed 43. Molecular recurrence detected 19 rate estimated to be 47% following discontinuation. Based on...
The superiority of the pediatric protocol for adolescents with acute lymphoblastic leukemia (ALL) has already been demonstrated, however, its efficacy in young adults remains unclear. ALL202-U was conducted to examine and feasibility a (AYAs) BCR-ABL-negative ALL. Patients aged 15-24 years (n=139) were treated same used B-ALL. primary objective this study assess disease-free survival (DFS) rate secondary aims toxicity, complete remission (CR) overall (OS) rate. CR 94%. 5-year DFS OS rates...
Key Points KIT exon 17 mutation is a poor prognostic factor in AML patients with RUNX1-RUNX1T1, but not those CBFB-MYH11. NRAS
Abstract Background: Even after the introduction of all‐ trans retinoic acid (ATRA), early hemorrhagic death remains a major cause remission induction failure for acute promyelocytic leukemia (APL). Methods: To investigate severe complications during therapy with respect to incidence, risk factors, and influence on outcome. Results were analyzed 279 patients enrolled in APL97 study conducted by Japan Adult Leukemia Study Group (JALSG). Results: Severe hemorrhage occurred 18 (6.5%). Although...
Summary The clinical significance of minimal residual disease (MRD) is uncertain in patients with Philadelphia chromosome‐positive acute lymphoblastic leukaemia (Ph+ ALL) treated imatinib‐combined chemotherapy. Here we report the results prospective MRD monitoring 100 adult patients. Three hundred and sixty‐seven follow‐up bone marrow samples, collected at predefined time points during a uniform treatment protocol, were analysed for BCR‐ABL1 transcripts by quantitative reverse transcription...
Azacitidine is a mainstay of therapy for myelodysplastic syndrome (MDS)-related diseases. The purpose our study to elucidate the effect gene mutations on hematological response and overall survival (OS), particularly focusing their posttreatment clone size. We enrolled total 449 patients with MDS or related myeloid neoplasms. They were analyzed in pretreatment (n = 449) 289) bone marrow samples using targeted-capture sequencing assess impact size treatment outcomes. In Cox proportional...
Anthracyclines are effective antineoplastic drugs, but they frequently cause dose-related cardiotoxicity. The cardiotoxicity of conventional anthracycline therapy highlights a need to search for methods that highly sensitive and capable predicting cardiac dysfunction. We measured the plasma level brain natriuretic peptide (BNP) determine whether BNP might serve as simple diagnostic indicator anthracycline-induced in patients with acute leukemia treated daunorubicin (DNR)-containing regimen....
Although tyrosine kinase inhibitors (TKIs) have significantly improved the prognosis of chronic myeloid leukemia (CML), ability TKIs to eradicate CML remains uncertain and patients must continue TKI therapy for indefinite periods. In this study, we performed whole-exome sequencing identify somatic mutations in 24 with newly diagnosed phase who were registered JALSG CML212 study. We identified 191 other than BCR-ABL1 fusion gene (median 8, range 1-17). Age, hemoglobin concentration white...